Etiroxate is a synthetic compound that acts as an inhibitor of phospholipase A2. It has been studied for its potential therapeutic effects in various inflammatory conditions, including arthritis and asthma. Etiroxate is synthesized through a multi-step process involving the reaction of 2-chloro-4-nitrophenol with 2-aminoethanol. Its mechanism of action involves blocking the enzyme phospholipase A2, which plays a key role in the production of inflammatory mediators such as prostaglandins and leukotrienes. Etiroxate has been shown to reduce inflammation in animal models and has been investigated in clinical trials for its efficacy in treating rheumatoid arthritis. However, its clinical use has been limited due to concerns about its potential side effects. Despite these limitations, etiroxate remains an interesting compound with potential therapeutic applications and continues to be studied for its pharmacological effects.'
etiroxate: RN given refers to (DL)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 65683 |
| CHEMBL ID | 2104225 |
| CHEBI ID | 135891 |
| SCHEMBL ID | 554818 |
| MeSH ID | M0055451 |
| Synonym |
|---|
| etiroxate |
| ethyl 2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-2-methylpropanoate |
| FT-0668421 |
| 0s3ldn5p7h , |
| 17365-01-4 |
| etiroxatum [inn-latin] |
| etiroxato |
| etiroxato [inn-spanish] |
| alpha-methyl-dl-thyroxine ethyl ester |
| etiroxatum |
| unii-0s3ldn5p7h |
| etiroxate [inn] |
| etiroxate [who-dd] |
| etiroxate [mi] |
| CHEMBL2104225 |
| SCHEMBL554818 |
| 5-amino-2-trifluoromethyl-isonicotinicacid |
| sr-01000945049 |
| SR-01000945049-1 |
| CHEBI:135891 |
| AKOS030255630 |
| tyrosine, o-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-alpha-methyl-, ethyl ester |
| Q27237167 |
| dl-alpha-methyl-thyroxine ethyl ester |
| o-(4-hydroxy-3,5-diiodo-phenyl)-3,5-diiodo-alpha-methyl-dl-tyrosine ethyl ester |
| DTXSID30864773 |
| ethyl o-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-alpha-methyltyrosinate |
| HY-111983 |
| CS-0094790 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " With initial values below 350 mg/100 ml the difference in the cholesterol decrease between the two dosage groups is not therapeutically relevant." | ( [Therapy of hyperlipoproteinemia type IIa and IIb with etiroxate-HCl. Dose-response comparison]. Banz, H; Gall, FP, 1979) | 0.51 |
| Class | Description |
|---|---|
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 10 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.62) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (45.45%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (54.55%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||